1.Amino acid formula as a new strategy for diagnosing cow´s milk allergy in infants: is it cost-effective?
Morais MB1, Spolidoro JV2,3, Vieira MC2,4, Cardoso AL5, Clark O6, Nishikawa A6, Castro AP5. J Med Econ. 2016 May 6:1-21. [Epub ahead of print]
OBJECTIVE: To estimate the cost-effectiveness of a new strategy that uses an amino acid formula in the elimination diet of infants with suspected cow's milk allergy (CMA).
2.L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.
Biteau K1, Guiho R1, Chatelais M1, Taurelle J1, Chesneau J1, Corradini N2, Heymann D1, Redini F3. Am J Cancer Res. 2016 Feb 15;6(3):677-89. eCollection 2016.
Osteosarcoma, the most frequent malignant primary bone tumor in pediatric patients is characterized by osteolysis promoting tumor growth. Lung metastasis is the major bad prognosis factor of this disease. Zoledronic Acid (ZA), a potent inhibitor of bone resorption is currently evaluated in phase III randomized studies in Europe for the treatment of osteosarcoma and Ewing sarcoma. The beneficial effect of the liposomal form of Muramyl-TriPeptide-Phosphatidyl Ethanolamine (L-mifamurtide, MEPACT®), an activator of macrophage populations has been demonstrated to eradicate lung metastatic foci in osteosarcoma. The objective of this study was to evaluate the potential therapeutic benefit and the safety of the ZA and L-mifamurtide combination in preclinical models of osteosarcoma, as a prerequisite before translation to patients. The effects of ZA (100 μg/kg) and L-mifamurtide (1 mg/kg) were investigated in vivo in xenogeneic and syngeneic mice models of osteosarcoma, at clinical (tumor proliferation, spontaneous lung metastases development), radiological (bone microarchitecture by microCT analysis), biological and histological levels.
